title: Gene therapy for malignant neoplasms of the CNS.
abstract: Five different gene transfer protocols have progressed into human clinical trials for the treatment of brain tumors. Two utilize the in vivo transfer of the Herpes Simplex-thymidine kinase (HS-tk) gene by either retroviral or adenoviral gene transfer. HS-tk confers a sensitivity to the anti-herpes drug ganciclovir (GCV). Insertion of HS-tk into tumors and subsequent treatment with GCV has successfully eliminated tumors in experimental animal models despite less than a 100% gene transfer efficiency. This phenomenon, the 'bystander effect', allows the destruction of neighboring tumor cells not transduced with HS-tk. Two other approaches use ex vivo gene transfer of either the IL-2 or antisense insulin-like growth factor type 1 (IGF-1) genes into autologous tumor cells. In animal models, tumor cells genetically altered with antisense IGF-1 or IL-2 genes induce a potent cell-mediated antitumor response. The fifth approach uses the genetic modification of hematopoietic stem cells instead of tumor cells. In this approach, the multiple drug resistance (MDR-1) gene is transferred into stem cells to protect them from the toxic effects of certain chemotherapy drugs. This may allow the administration of higher doses without increasing bone marrow toxicity. Together, these clinical trials will provide critical information needed to develop improved gene transfer technologies for humans and to attain clinical benefit for cancer patients.
authors.affiliation: Gene Therapy Research and Clinical Affairs, OncorPharm, Gaithersburg, MD 20877, USA.
authors.forename: K W
authors.initials: KW
authors.lastname: Culver
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000628:therapy*; D002648:Child; D002986:Clinical Trials as Topic; D016373:DNA, Antisense / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D015774:Ganciclovir / Q000627:therapeutic use; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D007376:Interleukin-2 / Q000235:genetics; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D016879:Salvage Therapy; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors / Q000235:genetics; D014162:Transfection
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000998:Antiviral Agents; D016373:DNA, Antisense; D007376:Interleukin-2; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013937:Thymidine Kinase; D015774:Ganciclovir